Evidence map›Paper›PMID 41732204›Full record

ArticleMolecular therapy. Nucleic acids2026

Non-cytolytic re-engineering of a viral vaccine vector enables durable effector-memory T cell immunity by reinforcing type I IFN induction.

Matias Ciancaglini, Robin Avanthay, Anna-Friederike Marx, Tiago Abreu-Mota, Davide Finozzi, Jonas Fixemer, Florian Geier, Dominik Burri, Ingrid Wagner, Ilena Vincenti and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Matias CiancagliniDepartment of Biomedicine, Division of Experimental Virology, University of Basel, 4009 Basel, Switzerland.
Robin AvanthayInstitute of Virology and Immunology, 3147 Mittelhäusern, Switzerland.
Anna-Friederike MarxDepartment of Biomedicine, Division of Experimental Virology, University of Basel, 4009 Basel, Switzerland.
Tiago Abreu-MotaDepartment of Biomedicine, Division of Experimental Virology, University of Basel, 4009 Basel, Switzerland.
Davide FinozziDepartment of Biomedicine, Division of Experimental Virology, University of Basel, 4009 Basel, Switzerland.
Jonas FixemerDepartment of Biomedicine, Division of Experimental Virology, University of Basel, 4009 Basel, Switzerland.
Florian GeierDepartment of Biomedicine, Bioinformatics Core Facility, University of Basel, 4031 Basel, Switzerland.
Dominik BurriDepartment of Biomedicine, Bioinformatics Core Facility, University of Basel, 4031 Basel, Switzerland.
Ingrid WagnerDepartment of Pathology and Immunology, University of Geneva, 1211 Geneva, Switzerland.
Ilena VincentiDepartment of Pathology and Immunology, University of Geneva, 1211 Geneva, Switzerland.
Mario KreuzfeldtDepartment of Pathology and Immunology, University of Geneva, 1211 Geneva, Switzerland.
Doron MerklerDepartment of Pathology and Immunology, University of Geneva, 1211 Geneva, Switzerland.
Gert ZimmerInstitute of Virology and Immunology, 3147 Mittelhäusern, Switzerland.
Daniel D PinschewerDepartment of Biomedicine, Division of Experimental Virology, University of Basel, 4009 Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Replication-deficient viral vector systems hold promise for CD8 T cell-based vaccination, but the molecular mechanisms accounting for platform-specific differences in immunogenicity remain ill-defined. When comparing prototypic single-cycle vaccine delivery platforms, we found that lymphocytic choriomeningitis virus (rLCMV)-based vectors, which are non-cytolytic, elicited more durable and effector-memory-differentiated CD8 T cell responses than vectors based on cytolytic vesicular stomatitis virus (rVSV). Hence, we re-engineered rVSV to be non-cytolytic (rVSVMq). This vector induced more durable and effector-differentiated CD8 T cell memory than the parental rVSV, and it afforded superior protection against

Indexed as

CD8 T cellsMT: Delivery Strategiesnon-cytolytictype I interferonvaccinationvesicular stomatitis virusviral vectors

Identifiers

PMID41732204
PMCPMC12925560

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.